Loading…
Surgical management, DNA content, and patient survival in adrenal cortical carcinoma
Background. Surgical resection is the only potentially curative treatment for adrenal cortical carcinoma, yet the value of extended resection, palliative resection, and tumor DNA analysis remains unclear. Methods. The records of 23 patients with adrenal cortical carcinoma who underwent primary surgi...
Saved in:
Published in: | Surgery 1995-12, Vol.118 (6), p.1090-1098 |
---|---|
Main Authors: | , , , , , , , |
Format: | Article |
Language: | English |
Subjects: | |
Citations: | Items that this one cites Items that cite this one |
Online Access: | Get full text |
Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
cited_by | cdi_FETCH-LOGICAL-c389t-a14d053a89cf08b4fc4ea9a3691d93da70fe9ed9e6b86b74db6ed58bb7f5b20f3 |
---|---|
cites | cdi_FETCH-LOGICAL-c389t-a14d053a89cf08b4fc4ea9a3691d93da70fe9ed9e6b86b74db6ed58bb7f5b20f3 |
container_end_page | 1098 |
container_issue | 6 |
container_start_page | 1090 |
container_title | Surgery |
container_volume | 118 |
creator | Lee, Jeffrey E. Berger, David H. El-Naggar, Adel K. Hickey, Robert C. Vassilopoulou-Sellin, Rena Gagel, Robert F. Andrew Burgess, M. Evans, Douglas B. |
description | Background. Surgical resection is the only potentially curative treatment for adrenal cortical carcinoma, yet the value of extended resection, palliative resection, and tumor DNA analysis remains unclear.
Methods. The records of 23 patients with adrenal cortical carcinoma who underwent primary surgical resection at our institution were retrospectively reviewed. Flow cytometric DNA analysis was performed on primary tumor tissue from 14 patients.
Results. Sixteen of 23 patients underwent complete resection. For these 16 patients the median follow-up was 43 months, the actuarial median survival was 46 months, and the actuarial 5-year survival rate was 46%. The seven patients who underwent incomplete resection all died of disease with a median survival of 8.5 months. Isolated local recurrence as the first site of failure occurred in two patients. Only completeness of resection (p=0.004) and stage at presentation (p=0.006) were significant prognostic indicators. None of the following predicted a poor prognosis in patients who underwent complete resection: (1) need for extended resection, (2) presence of renal vein or inferior vena cava tumor thrombus, or (3) tumor aneuploidy (14 of 14 tumors were aneuploid).
Conclusions. Long-term survival is possible in patients with adrenal cortical carcinoma if complete, margin-negative tumor resection can be achieved. Isolated local recurrence is uncommon after complete resection. Because adrenal cortical carcinomas are consistently aneuploid, tumor DNA content is not a useful prognostic factor. |
doi_str_mv | 10.1016/S0039-6060(05)80119-9 |
format | article |
fullrecord | <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_77714969</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><els_id>S0039606005801199</els_id><sourcerecordid>77714969</sourcerecordid><originalsourceid>FETCH-LOGICAL-c389t-a14d053a89cf08b4fc4ea9a3691d93da70fe9ed9e6b86b74db6ed58bb7f5b20f3</originalsourceid><addsrcrecordid>eNqFkE1Lw0AQhhdRaq3-hEJOomB0tkk2uycp9ROKHlrPy35MykqT1N2k4L83TUuvnmaGed93mIeQMYV7CpQ9LAASETNgcAPZLQdKRSxOyJBmySTOE0ZPyfAoOScXIXwDgEgpH5BBngqaTfiQLBetXzmj1lGpKrXCEqvmLnr6mEamrpp-UJWNNqpx3RCF1m_dtlO7KlLWY9W1pvZNn2CUN66qS3VJzgq1Dnh1qCPy9fK8nL3F88_X99l0HpuEiyZWNLWQJYoLUwDXaWFSVEIlTFArEqtyKFCgFcg0ZzpPrWZoM651XmR6AkUyItf73I2vf1oMjSxdMLheqwrrNsg8z2kqmOiE2V5ofB2Cx0JuvCuV_5UU5I6m7GnKHSoJmexpyp1vfDjQ6hLt0XXA1-0f93vsvtw69DKYjpNB6zyaRtra_XPhD6UnhVg</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>77714969</pqid></control><display><type>article</type><title>Surgical management, DNA content, and patient survival in adrenal cortical carcinoma</title><source>ScienceDirect Journals</source><creator>Lee, Jeffrey E. ; Berger, David H. ; El-Naggar, Adel K. ; Hickey, Robert C. ; Vassilopoulou-Sellin, Rena ; Gagel, Robert F. ; Andrew Burgess, M. ; Evans, Douglas B.</creator><creatorcontrib>Lee, Jeffrey E. ; Berger, David H. ; El-Naggar, Adel K. ; Hickey, Robert C. ; Vassilopoulou-Sellin, Rena ; Gagel, Robert F. ; Andrew Burgess, M. ; Evans, Douglas B.</creatorcontrib><description>Background. Surgical resection is the only potentially curative treatment for adrenal cortical carcinoma, yet the value of extended resection, palliative resection, and tumor DNA analysis remains unclear.
Methods. The records of 23 patients with adrenal cortical carcinoma who underwent primary surgical resection at our institution were retrospectively reviewed. Flow cytometric DNA analysis was performed on primary tumor tissue from 14 patients.
Results. Sixteen of 23 patients underwent complete resection. For these 16 patients the median follow-up was 43 months, the actuarial median survival was 46 months, and the actuarial 5-year survival rate was 46%. The seven patients who underwent incomplete resection all died of disease with a median survival of 8.5 months. Isolated local recurrence as the first site of failure occurred in two patients. Only completeness of resection (p=0.004) and stage at presentation (p=0.006) were significant prognostic indicators. None of the following predicted a poor prognosis in patients who underwent complete resection: (1) need for extended resection, (2) presence of renal vein or inferior vena cava tumor thrombus, or (3) tumor aneuploidy (14 of 14 tumors were aneuploid).
Conclusions. Long-term survival is possible in patients with adrenal cortical carcinoma if complete, margin-negative tumor resection can be achieved. Isolated local recurrence is uncommon after complete resection. Because adrenal cortical carcinomas are consistently aneuploid, tumor DNA content is not a useful prognostic factor.</description><identifier>ISSN: 0039-6060</identifier><identifier>EISSN: 1532-7361</identifier><identifier>DOI: 10.1016/S0039-6060(05)80119-9</identifier><identifier>PMID: 7491528</identifier><language>eng</language><publisher>United States: Elsevier Inc</publisher><subject>Adenoma - genetics ; Adenoma - mortality ; Adenoma - surgery ; Adolescent ; Adrenal Cortex Neoplasms - genetics ; Adrenal Cortex Neoplasms - mortality ; Adrenal Cortex Neoplasms - surgery ; Adult ; Aged ; Aneuploidy ; Carcinoma - genetics ; Carcinoma - mortality ; Carcinoma - surgery ; Combined Modality Therapy ; DNA, Neoplasm - analysis ; Female ; Humans ; Male ; Middle Aged ; Mitotane - therapeutic use ; Neoplasm Metastasis ; Neoplasm Recurrence, Local ; Neoplasm Staging ; Prognosis ; Survival Rate</subject><ispartof>Surgery, 1995-12, Vol.118 (6), p.1090-1098</ispartof><rights>1995 Mosby-Year Book, Inc.</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c389t-a14d053a89cf08b4fc4ea9a3691d93da70fe9ed9e6b86b74db6ed58bb7f5b20f3</citedby><cites>FETCH-LOGICAL-c389t-a14d053a89cf08b4fc4ea9a3691d93da70fe9ed9e6b86b74db6ed58bb7f5b20f3</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><link.rule.ids>314,780,784,27924,27925</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/7491528$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Lee, Jeffrey E.</creatorcontrib><creatorcontrib>Berger, David H.</creatorcontrib><creatorcontrib>El-Naggar, Adel K.</creatorcontrib><creatorcontrib>Hickey, Robert C.</creatorcontrib><creatorcontrib>Vassilopoulou-Sellin, Rena</creatorcontrib><creatorcontrib>Gagel, Robert F.</creatorcontrib><creatorcontrib>Andrew Burgess, M.</creatorcontrib><creatorcontrib>Evans, Douglas B.</creatorcontrib><title>Surgical management, DNA content, and patient survival in adrenal cortical carcinoma</title><title>Surgery</title><addtitle>Surgery</addtitle><description>Background. Surgical resection is the only potentially curative treatment for adrenal cortical carcinoma, yet the value of extended resection, palliative resection, and tumor DNA analysis remains unclear.
Methods. The records of 23 patients with adrenal cortical carcinoma who underwent primary surgical resection at our institution were retrospectively reviewed. Flow cytometric DNA analysis was performed on primary tumor tissue from 14 patients.
Results. Sixteen of 23 patients underwent complete resection. For these 16 patients the median follow-up was 43 months, the actuarial median survival was 46 months, and the actuarial 5-year survival rate was 46%. The seven patients who underwent incomplete resection all died of disease with a median survival of 8.5 months. Isolated local recurrence as the first site of failure occurred in two patients. Only completeness of resection (p=0.004) and stage at presentation (p=0.006) were significant prognostic indicators. None of the following predicted a poor prognosis in patients who underwent complete resection: (1) need for extended resection, (2) presence of renal vein or inferior vena cava tumor thrombus, or (3) tumor aneuploidy (14 of 14 tumors were aneuploid).
Conclusions. Long-term survival is possible in patients with adrenal cortical carcinoma if complete, margin-negative tumor resection can be achieved. Isolated local recurrence is uncommon after complete resection. Because adrenal cortical carcinomas are consistently aneuploid, tumor DNA content is not a useful prognostic factor.</description><subject>Adenoma - genetics</subject><subject>Adenoma - mortality</subject><subject>Adenoma - surgery</subject><subject>Adolescent</subject><subject>Adrenal Cortex Neoplasms - genetics</subject><subject>Adrenal Cortex Neoplasms - mortality</subject><subject>Adrenal Cortex Neoplasms - surgery</subject><subject>Adult</subject><subject>Aged</subject><subject>Aneuploidy</subject><subject>Carcinoma - genetics</subject><subject>Carcinoma - mortality</subject><subject>Carcinoma - surgery</subject><subject>Combined Modality Therapy</subject><subject>DNA, Neoplasm - analysis</subject><subject>Female</subject><subject>Humans</subject><subject>Male</subject><subject>Middle Aged</subject><subject>Mitotane - therapeutic use</subject><subject>Neoplasm Metastasis</subject><subject>Neoplasm Recurrence, Local</subject><subject>Neoplasm Staging</subject><subject>Prognosis</subject><subject>Survival Rate</subject><issn>0039-6060</issn><issn>1532-7361</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>1995</creationdate><recordtype>article</recordtype><recordid>eNqFkE1Lw0AQhhdRaq3-hEJOomB0tkk2uycp9ROKHlrPy35MykqT1N2k4L83TUuvnmaGed93mIeQMYV7CpQ9LAASETNgcAPZLQdKRSxOyJBmySTOE0ZPyfAoOScXIXwDgEgpH5BBngqaTfiQLBetXzmj1lGpKrXCEqvmLnr6mEamrpp-UJWNNqpx3RCF1m_dtlO7KlLWY9W1pvZNn2CUN66qS3VJzgq1Dnh1qCPy9fK8nL3F88_X99l0HpuEiyZWNLWQJYoLUwDXaWFSVEIlTFArEqtyKFCgFcg0ZzpPrWZoM651XmR6AkUyItf73I2vf1oMjSxdMLheqwrrNsg8z2kqmOiE2V5ofB2Cx0JuvCuV_5UU5I6m7GnKHSoJmexpyp1vfDjQ6hLt0XXA1-0f93vsvtw69DKYjpNB6zyaRtra_XPhD6UnhVg</recordid><startdate>19951201</startdate><enddate>19951201</enddate><creator>Lee, Jeffrey E.</creator><creator>Berger, David H.</creator><creator>El-Naggar, Adel K.</creator><creator>Hickey, Robert C.</creator><creator>Vassilopoulou-Sellin, Rena</creator><creator>Gagel, Robert F.</creator><creator>Andrew Burgess, M.</creator><creator>Evans, Douglas B.</creator><general>Elsevier Inc</general><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7X8</scope></search><sort><creationdate>19951201</creationdate><title>Surgical management, DNA content, and patient survival in adrenal cortical carcinoma</title><author>Lee, Jeffrey E. ; Berger, David H. ; El-Naggar, Adel K. ; Hickey, Robert C. ; Vassilopoulou-Sellin, Rena ; Gagel, Robert F. ; Andrew Burgess, M. ; Evans, Douglas B.</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c389t-a14d053a89cf08b4fc4ea9a3691d93da70fe9ed9e6b86b74db6ed58bb7f5b20f3</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>1995</creationdate><topic>Adenoma - genetics</topic><topic>Adenoma - mortality</topic><topic>Adenoma - surgery</topic><topic>Adolescent</topic><topic>Adrenal Cortex Neoplasms - genetics</topic><topic>Adrenal Cortex Neoplasms - mortality</topic><topic>Adrenal Cortex Neoplasms - surgery</topic><topic>Adult</topic><topic>Aged</topic><topic>Aneuploidy</topic><topic>Carcinoma - genetics</topic><topic>Carcinoma - mortality</topic><topic>Carcinoma - surgery</topic><topic>Combined Modality Therapy</topic><topic>DNA, Neoplasm - analysis</topic><topic>Female</topic><topic>Humans</topic><topic>Male</topic><topic>Middle Aged</topic><topic>Mitotane - therapeutic use</topic><topic>Neoplasm Metastasis</topic><topic>Neoplasm Recurrence, Local</topic><topic>Neoplasm Staging</topic><topic>Prognosis</topic><topic>Survival Rate</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Lee, Jeffrey E.</creatorcontrib><creatorcontrib>Berger, David H.</creatorcontrib><creatorcontrib>El-Naggar, Adel K.</creatorcontrib><creatorcontrib>Hickey, Robert C.</creatorcontrib><creatorcontrib>Vassilopoulou-Sellin, Rena</creatorcontrib><creatorcontrib>Gagel, Robert F.</creatorcontrib><creatorcontrib>Andrew Burgess, M.</creatorcontrib><creatorcontrib>Evans, Douglas B.</creatorcontrib><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>MEDLINE - Academic</collection><jtitle>Surgery</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Lee, Jeffrey E.</au><au>Berger, David H.</au><au>El-Naggar, Adel K.</au><au>Hickey, Robert C.</au><au>Vassilopoulou-Sellin, Rena</au><au>Gagel, Robert F.</au><au>Andrew Burgess, M.</au><au>Evans, Douglas B.</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Surgical management, DNA content, and patient survival in adrenal cortical carcinoma</atitle><jtitle>Surgery</jtitle><addtitle>Surgery</addtitle><date>1995-12-01</date><risdate>1995</risdate><volume>118</volume><issue>6</issue><spage>1090</spage><epage>1098</epage><pages>1090-1098</pages><issn>0039-6060</issn><eissn>1532-7361</eissn><abstract>Background. Surgical resection is the only potentially curative treatment for adrenal cortical carcinoma, yet the value of extended resection, palliative resection, and tumor DNA analysis remains unclear.
Methods. The records of 23 patients with adrenal cortical carcinoma who underwent primary surgical resection at our institution were retrospectively reviewed. Flow cytometric DNA analysis was performed on primary tumor tissue from 14 patients.
Results. Sixteen of 23 patients underwent complete resection. For these 16 patients the median follow-up was 43 months, the actuarial median survival was 46 months, and the actuarial 5-year survival rate was 46%. The seven patients who underwent incomplete resection all died of disease with a median survival of 8.5 months. Isolated local recurrence as the first site of failure occurred in two patients. Only completeness of resection (p=0.004) and stage at presentation (p=0.006) were significant prognostic indicators. None of the following predicted a poor prognosis in patients who underwent complete resection: (1) need for extended resection, (2) presence of renal vein or inferior vena cava tumor thrombus, or (3) tumor aneuploidy (14 of 14 tumors were aneuploid).
Conclusions. Long-term survival is possible in patients with adrenal cortical carcinoma if complete, margin-negative tumor resection can be achieved. Isolated local recurrence is uncommon after complete resection. Because adrenal cortical carcinomas are consistently aneuploid, tumor DNA content is not a useful prognostic factor.</abstract><cop>United States</cop><pub>Elsevier Inc</pub><pmid>7491528</pmid><doi>10.1016/S0039-6060(05)80119-9</doi><tpages>9</tpages></addata></record> |
fulltext | fulltext |
identifier | ISSN: 0039-6060 |
ispartof | Surgery, 1995-12, Vol.118 (6), p.1090-1098 |
issn | 0039-6060 1532-7361 |
language | eng |
recordid | cdi_proquest_miscellaneous_77714969 |
source | ScienceDirect Journals |
subjects | Adenoma - genetics Adenoma - mortality Adenoma - surgery Adolescent Adrenal Cortex Neoplasms - genetics Adrenal Cortex Neoplasms - mortality Adrenal Cortex Neoplasms - surgery Adult Aged Aneuploidy Carcinoma - genetics Carcinoma - mortality Carcinoma - surgery Combined Modality Therapy DNA, Neoplasm - analysis Female Humans Male Middle Aged Mitotane - therapeutic use Neoplasm Metastasis Neoplasm Recurrence, Local Neoplasm Staging Prognosis Survival Rate |
title | Surgical management, DNA content, and patient survival in adrenal cortical carcinoma |
url | http://sfxeu10.hosted.exlibrisgroup.com/loughborough?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2024-12-21T01%3A52%3A46IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Surgical%20management,%20DNA%20content,%20and%20patient%20survival%20in%20adrenal%20cortical%20carcinoma&rft.jtitle=Surgery&rft.au=Lee,%20Jeffrey%20E.&rft.date=1995-12-01&rft.volume=118&rft.issue=6&rft.spage=1090&rft.epage=1098&rft.pages=1090-1098&rft.issn=0039-6060&rft.eissn=1532-7361&rft_id=info:doi/10.1016/S0039-6060(05)80119-9&rft_dat=%3Cproquest_cross%3E77714969%3C/proquest_cross%3E%3Cgrp_id%3Ecdi_FETCH-LOGICAL-c389t-a14d053a89cf08b4fc4ea9a3691d93da70fe9ed9e6b86b74db6ed58bb7f5b20f3%3C/grp_id%3E%3Coa%3E%3C/oa%3E%3Curl%3E%3C/url%3E&rft_id=info:oai/&rft_pqid=77714969&rft_id=info:pmid/7491528&rfr_iscdi=true |